Advertisement

Topics

A Phase 1 Study of MKC-1 in Patients With Refractory Hematologic Malignancies

2010-07-15 17:00:00 | BioPortfolio

Summary

The main objectives of this study are to evaluate the side effects of MKC-1 and to determine a safe dose of MKC-1 for future studies in patients with hematological malignancies

Study Design

Allocation: Non-Randomized, Control: Uncontrolled, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Conditions

Hematological Malignancies

Intervention

MKC-1

Location

Princess Margaret Hospital
Toronto
Canada

Status

Completed

Source

EntreMed

Results (where available)

View Results

Links

Published on BioPortfolio: 2010-07-15T17:00:00-0400

Clinical Trials [552 Associated Clinical Trials listed on BioPortfolio]

Allogeneic Immunotherapy for Hematological Malignancies by Selective Depletion of Regulatory T Cells

The investigators have previously shown the absence of toxicity of Treg-depleted-DLI and the possibility to triggering alloreactivity (GVHD/GVT) in relapsing patients dealing with hematolo...

MS Detection of Somatic Mutations in Hematological Malignancies

Detection of somatic mutations in hematological malignancies is now routinely assessed by NGS sequencing. This powerful approach is nevertheless time consuming and its costs represent limi...

Intrabone Infusion of Cord Blood in Adults With Hematological Malignancies

The purpose of this study is to evaluate the engraftment of donor hemopoiesis (proportion of transplanted patients with successful engraftment at day +42) in adult patients affected by hig...

Thymosin Alfa 1 in Recipients of Allogeneic Hematopoietic Transplantation for Hematological Malignancies

The purpose of this trial is to determine safety and efficacy of 16 weeks treatment with thymosin alpha 1 given at 1.6 mg dose once daily by subcutaneous injection in adult patients with h...

Study of a Reduced-toxicity "Submyeloablative" Conditioning Regimen Prior to Allogeneic Stem Cell Transplantation in Patients With Hematological Malignancies

The goal of this prospective study is to assess the overall mortality (whether related to relapse/progression or toxicity - TRM-) at one year after allogeneic stem cell transplantation pre...

PubMed Articles [1127 Associated PubMed Articles listed on BioPortfolio]

Multiple functions of Ikaros in hematological malignancies, solid tumor and autoimmune diseases.

Ikaros, encoded by IKZF1 (Ikaros family zinc finger 1), is an important transcription factor in the control of lymphocyte specification and differentiation. Multiple functions of Ikaros have been exer...

What the internist should know about stem cell transplant in the elderly patient.

Most hematological malignancies are increasing in frequency with age. Allogeneic hematopoietic cell transplantation (allo-HCT) is a potentially curative therapeutic option for patients with malignant ...

Co-administration of proton pump inhibitors and/or of steroids may be a risk factor for low trough concentrations of posaconazole delayed-released tablets in adult patients with hematological malignancies.

The aim of this study was to determine clinical variables associated with posaconazole exposure among adult patients with hematological malignancies who received posaconazole tablets for prophylaxis o...

Phase I Study of Domatinostat (4SC-202), a class I Histone Deacetylase Inhibitor in Patients with Advanced Hematological Malignancies.

Domatinostat (4SC-202) is a selective class I histone deacetylase inhibitor (HDACi). This phase I study investigated safety, tolerability, pharmacokinetics (PK), pharmacodynamics and anti-tumor activi...

Antibiotic Resistance and Risk Factors for Mortality of Blood Stream Infections (BSIs) with in Patients with Hematological Malignancies.

To analyze the risk factors for mortality of blood stream infections (BSIs) caused by in the patients with hematological malignancies.

Medical and Biotech [MESH] Definitions

Use of HIRUDINS as an anticoagulant in the treatment of cardiological and hematological disorders.

A hematopoietic growth factor which promotes proliferation and maturation of neutrophil granulocytes. Clinically it is effective in decreasing the incidence of febrile neutropenia in patients with non-myeloid malignancies receiving myelosuppressive therapy or in reducing the duration of neutropenia and neutropenia-related clinical sequelae in patients with non-myeloid malignancies undergoing myeloblastive chemotherapy followed by BMT. It has also been used in AIDS patients with CMV retinitis being treated with GANCICLOVIR. (Gelman CR, Rumack BH & Hess AJ (eds): DRUGDEX(R) System. MICROMEDEX, Inc., Englewood, Colorado (Edition expires 11/30/95))

A tetracyclic compound with antidepressant effects. It may cause drowsiness and hematological problems. Its mechanism of therapeutic action is not well understood, although it apparently blocks alpha-adrenergic, histamine H1, and some types of serotonin receptors.

An alkylating agent of value against both hematologic malignancies and solid tumors.

A condition caused by a brief whole body exposure to more than one sievert dose equivalent of radiation. Acute radiation syndrome is initially characterized by ANOREXIA; NAUSEA; VOMITING; but can progress to hematological, gastrointestinal, neurological, pulmonary, and other major organ dysfunction.

More From BioPortfolio on "A Phase 1 Study of MKC-1 in Patients With Refractory Hematologic Malignancies"

Advertisement
Quick Search
Advertisement
Advertisement

 

Searches Linking to this Trial